Company
Headquarters: Watertown, MA, United States
Employees: 155
CEO: Dr. Jay R. Luly
$416.2 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $73.6 M |
| EBITDA | $-139,578,000 |
| Gross Profit TTM | $0 |
| Profit Margin | -187.77% |
| Operating Margin | -193.78% |
| Quarterly Revenue Growth | -23.70% |
Enanta Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ENTA
Stock: FSX: 9EP